To assess the risk of gastric non-cardia adenocarcinoma associated with long-term proton pump inhibitor (PPI) use.
Key Findings:
Long-term PPI use was observed in 10.2% of cases and 9.5% of controls.
The elevated risk in unadjusted models was not statistically significant after adjustment.
Similar null results were found for long-term histamine-2 receptor antagonist use.
Interpretation:
After adjusting for confounding factors, long-term PPI use does not increase the risk of gastric non-cardia adenocarcinoma compared to nonuse.
Limitations:
Observational case-control design may introduce residual confounding.
Certain variables, such as dietary exposures and family history, were not captured.
Rare conditions like prior benign gastric surgery were too uncommon for meaningful analysis.
Conclusion:
The study suggests no significant association between long-term PPI use and gastric non-cardia adenocarcinoma risk, emphasizing the importance of bias prevention in research.
